10.1136/jitc-2022-005457 - Nivolumab after selective internal ra...

This document has been corrected

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

10.1136/jitc-2022-005457

Published Online: 2022-11-?

Journal: Journal for ImmunoTherapy of Cancer•Publisher: BMJ

Authors: Ana Matilla•Bruno Sangro•Carlos Gómez-Martin•Jose I Bilbao•Jose Luis Lledó•Josepmaria Argemí•Juan Ignacio Arenas•Laura Márquez•Leonardo Da Fonseca•Macarena Rodriguez-Fraile•Manuel de la Torre-Aláez•Maria Reig•Maria Varela•Mercedes Iñarrairaegui•Milagros Testillano•Sara Lorente

This document has been corrected

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

10.1136/jitc-2022-005457

Published Online: 2022-11-?

Journal: Journal for ImmunoTherapy of Cancer

NOW

2023-03-10•Correction

Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

10.1136/jitc-2022-005457corr1

* information provided by CrossRef

2023-03-10•Correction

10.1136/jitc-2022-005457corr1

* information provided by CrossRef

2022-11-?•Published

2023-03-10•Correction

Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

10.1136/jitc-2022-005457corr1

* information provided by CrossRef

This document has been corrected

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

10.1136/jitc-2022-005457

Published Online: 2022-11-?

Journal: Journal for ImmunoTherapy of Cancer•Publisher: BMJ